DOCSLIB.ORG

Enfortumab Vedotin for Locally Advanced Or Metastatic Urothelial

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Enfortumab Vedotin for Locally Advanced Or Metastatic Urothelial Author Manuscript Published OnlineFirst on September 22, 2020; DOI: 10.1158/1078-0432.CCR-20-2275 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Title: FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma Authors: Elaine Chang1, Chana Weinstock1, Lijun Zhang1, Rosane Charlab1, Sarah E. Dorff1, Yutao Gong1, Vicky Hsu1, Fang Li1, Tiffany K. Ricks1, Pengfei Song1, Shenghui Tang1, Peter E. Waldron1, Jingyu Yu1, Eias Zahalka1, Kirsten B. Goldberg2, Richard Pazdur1,2, Marc R. Theoret1,2, Amna Ibrahim1, Julia A. Beaver1 Authors’ Affiliations: 1Center for Drug Evaluation and Research, U.S. Food and Drug Administration; 2Oncology Center of Excellence, U.S. Food and Drug Administration Running Title: FDA Approval Summary: Enfortumab vedotin Corresponding Author: Elaine Chang, Office of Oncologic Diseases, CDER, U.S. Food and Drug Administration, WO22 Room 2169, 10903 New Hampshire Avenue, Silver Spring, MD 20993. Phone 240-402-2628. Fax: 301-796-9909. Email: [email protected]. Note: This is a U.S. Government work. There are no restrictions on its use. Disclosure of Potential Conflicts of Interest: The authors report no financial interests or relationships with the commercial sponsors of any products discussed in this report. Word count: Abstract 200; Text 2996; Tables = 3; Figures = 1 ; References = 18 1 Downloaded from clincancerres.aacrjournals.org on September 26, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 22, 2020; DOI: 10.1158/1078-0432.CCR-20-2275 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract On December 18, 2019, the Food and Drug Administration (FDA) granted accelerated approval to enfortumab vedotin-ejfv (PADCEVTM; Astellas and Seattle Genetics) for treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. Substantial evidence of effectiveness for this application is obtained from Cohort 1 of the single arm, multicenter study EV-201. Patients received enfortumab vedotin (EV) 1.25 mg/kg (up to a maximum dose of 125 mg) intravenously on Days 1, 8, and 15 of 28-day cycles until disease progression or unacceptable toxicity. Confirmed objective response rate in the 125-patient efficacy population determined by blinded independent central review was 44% (95% CI: 35.1, 53.2), with complete responses in 12%. Median response duration was 7.6 months (95% CI: 6.3, not estimable). Grade 3-4 adverse reactions occurred in 73% of patients. Hyperglycemia, peripheral neuropathy, ocular disorders, skin reactions, infusion site extravasations, and embryo-fetal toxicity are labeled as warnings and precautions for EV. The article summarizes the data and the FDA thought process supporting accelerated approval of EV. This approval may be contingent upon verification and description of clinical benefit in confirmatory trial(s). 2 Downloaded from clincancerres.aacrjournals.org on September 26, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 22, 2020; DOI: 10.1158/1078-0432.CCR-20-2275 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Introduction Urinary bladder cancer accounted for approximately 17,670 deaths in 2019 in the U.S.1 Although most urothelial carcinomas are non-muscle invasive at diagnosis and can be managed effectively with intravesical therapies and/or surgical resection, about half of patients relapse after cystectomy, with distant metastases being more common than local relapse.2 Additionally, approximately 4% of patients have locally advanced or metastatic disease at diagnosis.1 Standard of care for the first line treatment of patients with advanced disease is platinum-containing combination chemotherapy, such as gemcitabine and cisplatin (GC) or methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC).3 In the U.S., pembrolizumab has received regular approval for the treatment of locally advanced or metastatic urothelial carcinoma (la/mUC) after initial chemotherapy treatment. Both pembrolizumab and atezolizumab have received accelerated approval for the frontline treatment of patients with PD-L1-positive la/mUC and who are not eligible for a platinum-containing regimen, and for all treatment-naïve patients who are chemotherapy-ineligible in frontline. Avelumab has received regular approval for first-line maintenance treatment of patients without disease progression after initial platinum-containing chemotherapy, in addition to approval in the second-line setting. Durvalumab, and nivolumab have also received accelerated approval in the second line. Patients with la/mUC previously treated with a platinum-containing regimen and immunotherapy have limited therapeutic options (Table 1). Recently, erdafitinib received accelerated approval by the FDA for patients with susceptible FGFR3 or FGFR2 alterations, although this only represents approximately 20% of patients with urothelial carcinoma of the bladder and almost 40% of patients with upper tract urothelial carcinoma.4-6 Other chemotherapeutic agents, including taxanes, may also be used in this setting. None of these other 3 Downloaded from clincancerres.aacrjournals.org on September 26, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 22, 2020; DOI: 10.1158/1078-0432.CCR-20-2275 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. single agent chemotherapies are curative and overall response rate (ORR) and duration of response (DOR) are low. Enfortumab vedotin-ejfv (hereafter, EV) is a Nectin-4-directed antibody-drug conjugate and an original biologic that has not previously received marketing approval for any indication by any regulatory agency. It was granted breakthrough therapy designation in 2018, meeting criteria with preliminary clinical evidence indicating that the drug could demonstrate substantial improvement over available therapy on a clinically significant endpoint. Upon submission of the marketing application in 2019, EV was granted priority review. The priority review designation is granted if the drug demonstrates evidence of improved effectiveness or safety, and sets a 6- month timeline for FDA review. However, FDA reviewed and approved EV in approximately 3 months. EV was the first biologic approved that specifically targets Nectin-4 as a directed antibody to deliver a toxic microtubule inhibitor conjugated payload. The indication is for the treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. Herein we discuss FDA’s benefit- risk analysis of the marketing application that led to the approval of EV for patients with refractory la/mUC. Chemistry EV is a Nectin-4-directed antibody-drug conjugate (ADC). The ADC is a fully human IgG1-kappa antibody conjugated to the microtubule-disrupting agent, monomethyl auristatin E (MMAE), via a protease-cleavable maleimidocaproyl valine-citrulline linker (SGD-1006). Nectin-4 is a transmembrane protein expressed in multiple cancers, particularly urothelial, breast, lung, pancreatic, and ovarian cancers.7 Higher levels of expression of Nectin-4 have been 4 Downloaded from clincancerres.aacrjournals.org on September 26, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 22, 2020; DOI: 10.1158/1078-0432.CCR-20-2275 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. associated with disease progression and/or poor prognosis in breast, lung, and pancreatic cancers.8-10 Nonclinical Pharmacology and Toxicology The anticancer activity of EV was demonstrated by the ADC binding to Nectin-4– expressing cells, followed by endocytosis of the ADC–Nectin-4 complex, and MMAE release via proteolytic cleavage of the linker. MMAE disrupts microtubule dynamics, subsequently inducing cell cycle arrest and finally triggering apoptotic cell death. Results from intravenous repeat-dose toxicity studies in rats for up to 13 weeks indicated the potential for EV to impair male reproductive function and fertility. In rats and monkeys, additional target organs of toxicities included skin, bone marrow, liver, ocular system, and gastrointestinal tract. MMAE was reported to be genotoxic in the in vivo rat bone marrow micronucleus study by the aneugenic mechanism. In the dose-range-finding embryo-fetal development study in rats, EV was administered intravenously during the period of organogenesis to pregnant rats at maternal exposures approximately similar to the exposures at the recommended human dose of 1.25 mg/kg. EV caused maternal toxicity, embryo-fetal lethality, skeletal anomalies and structural malformations that included gastroschisis, malrotated hindlimb, absent forepaw, malpositioned internal organs and fused cervical arch. Clinical Pharmacology Dose Selection The proposed dosing regimen was supported by EV-201 and exposure-response analysis for efficacy and safety. The proposed dosing regimen of EV is 1.25 mg/kg (up to a maximum
Load more

Recommended publications
  • Prior Approaches and Future Directions Marna Williams1, Anna Spreafico2, Kapil Vashisht3, Mary Jane Hinrichs4
    Author Manuscript Published OnlineFirst on June 16, 2020; DOI: 10.1158/1535-7163.MCT-19-0993 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Patient Selection Strategies to Maximize Therapeutic Index of Antibody Drug Conjugates: Prior Approaches and Future Directions Marna Williams1, Anna Spreafico2, Kapil Vashisht3, Mary Jane Hinrichs4 1Translational Medicine, Oncology, AstraZeneca, Gaithersburg, USA 2Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada 3AstraZeneca, Gaithersburg, USA. 4Early Development Oncology, Ipsen LLC, USA Corresponding author: Marna Williams Email: [email protected] Postal address: One MedImmune Way, Gaithersburg, MD, 20878 Phone: 301-398-1241 Fax: 240-306-1545 Running title Patient Selection Strategies for Antibody Drug Conjugates Keywords Antibody drug conjugates; therapeutic index; patient selection; biomarkers; cancer Conflicts of interest This study was funded by AstraZeneca. MW, KV and MJH are all current or former employees of AstraZeneca with stock/stock options in AstraZeneca. AS has been Advisory Board Consultant to Merck, Bristol-Myers Squibb, Novartis, Oncorus, Janssen, and has received Grant/Research support from Novartis, Bristol-Myers Squibb, Symphogen AstraZeneca/Medimmune, Merck, Bayer, Surface Oncology, Northern Biologics, Janssen Oncology/Johnson & Johnson, Roche, Regeneron, and Alkermes. Word count: Abstract: 197 Manuscript: 5,268 (excluding abstract) + 683 figure/table legends and footnotes Figures/tables: 5 (as agreed) 1 Downloaded from mct.aacrjournals.org on September 24, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on June 16, 2020; DOI: 10.1158/1535-7163.MCT-19-0993 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
    antibodies Review Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients Andrew T. Lucas 1,2,3,*, Ryan Robinson 3, Allison N. Schorzman 2, Joseph A. Piscitelli 1, Juan F. Razo 1 and William C. Zamboni 1,2,3 1 University of North Carolina (UNC), Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA; [email protected] (J.A.P.); [email protected] (J.F.R.); [email protected] (W.C.Z.) 2 Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] 3 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-919-966-5242; Fax: +1-919-966-5863 Received: 30 November 2018; Accepted: 22 December 2018; Published: 1 January 2019 Abstract: The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous benefits compared to traditional small molecule drugs, though their clinical use still requires optimization. The pharmacology of mAbs/ADCs is complex and because ADCs are comprised of multiple components, individual agent characteristics and patient variables can affect their disposition. To further improve the clinical use and rational development of these agents, it is imperative to comprehend the complex mechanisms employed by antibody-based agents in traversing numerous biological barriers and how agent/patient factors affect tumor delivery, toxicities, efficacy, and ultimately, biodistribution.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Australian Public Assessment for Polatuzumab Vedotin
    Australian Public Assessment Report for Polatuzumab vedotin Proprietary Product Name: Polivy Sponsor: Roche Products Pty Ltd December 2019 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices. • The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance) when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About AusPARs • An Australian Public Assessment Report (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. • AusPARs are prepared and published by the TGA. • An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations and extensions of indications. • An AusPAR is a static document; it provides information that relates to a submission at a particular point in time. • A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • Pharmacokinetics of Polatuzumab Vedotin in Combination with R/G‑CHP in Patients with B‑Cell Non‑Hodgkin Lymphoma
    Cancer Chemotherapy and Pharmacology (2020) 85:831–842 https://doi.org/10.1007/s00280-020-04054-8 ORIGINAL ARTICLE Pharmacokinetics of polatuzumab vedotin in combination with R/G‑CHP in patients with B‑cell non‑Hodgkin lymphoma Colby S. Shemesh1 · Priya Agarwal1 · Tong Lu1 · Calvin Lee2 · Randall C. Dere3 · Xiaobin Li1 · Chunze Li1 · Jin Y. Jin1 · Sandhya Girish1 · Dale Miles1 · Dan Lu1 Received: 4 October 2019 / Accepted: 3 March 2020 / Published online: 28 March 2020 © The Author(s) 2020 Abstract Purpose The phase Ib/II open-label study (NCT01992653) evaluated the antibody-drug conjugate polatuzumab vedotin (pola) plus rituximab/obinutuzumab, cyclophosphamide, doxorubicin, and prednisone (R/G-CHP) as frst-line therapy for B-cell non-Hodgkin lymphoma (B-NHL). We report the pharmacokinetics (PK) and drug–drug interaction (DDI) for pola. Methods Six or eight cycles of pola 1.0–1.8 mg/kg were administered intravenously every 3 weeks (q3w) with R/G-CHP. Exposures of pola [including antibody-conjugated monomethyl auristatin E (acMMAE) and unconjugated MMAE] and R/G-CHP were assessed by non-compartmental analysis and/or descriptive statistics with cross-cycle comparisons to cycle 1 and/or after multiple cycles. Pola was evaluated as a potential victim and perpetrator of a PK drug–drug interaction with R/G-CHP. Population PK (popPK) analysis assessed the impact of prior treatment status (naïve vs. relapsed/refractory) on pola PK. Results Pola PK was similar between treatment arms and independent of line of therapy. Pola PK was dose proportional from 1.0 to 1.8 mg/kg with R/G-CHP.
    [Show full text]
  • An Update on Antibody Drug Conjugates
    Pharmacy & Pharmacology International Journal Review Article Open Access An update on antibody drug conjugates Abstract Volume 6 Issue 2 - 2018 Antibody Drug Conjugates (ADCs) are an emerging class of biopharmaceuticals in which a target-specific monoclonal antibody combines with small molecule Pavankumar Tandra,1 Jairam Krishnamurthy,1 chemotherapeutic agents. ADCs resemble the “magic bullet” version of Paul Ehrlich. Venkatasunil Bendi,2 Avyakta Kallam1 Paul Ehrlich, a German chemist, was the first who envisioned the concept of “magic 1Division of hematology-oncology, University of Nebraska bullet” in which a highly specific drug would be delivered to the target diseased Medical Center, USA tissue while leaving the healthy tissues intact. ADCs widen the therapeutic index of 2Clinical observer in academic neurology, University of the cytotoxic chemotherapy and enhance their potency. FDA approved four ADCs Nebraska Medical center, USA thus far. Some are currently undergoing development (see picture). In this review, we will focus on ADCs approved by the FDA thus far in solid tumors as well as in Correspondence: Pavankumar Tandra, Division of hematology- hematological malignancies. Also, we will discuss the ongoing clinical trials using oncology, University of Nebraska Medical Center, Omaha, NE 68116,USA, Email [email protected] these novel therapeutics. Received: February 05, 2018 | Published: March 14, 2018 Introduction peptide linker.2 CD30 expressing cells internalize BV upon attachment to the receptor. Once internalized, the peptide linker is cleaved, Antibody Drug Conjugates (ADCs) are an emerging class of allowing MMAE to be released and resulting in apoptosis.3 CD30 is biopharmaceuticals in which a target-specific monoclonal antibody expressed in Reed-Sternberg cells, thus making BV a potential agent combines with small molecule chemotherapeutic agents.
    [Show full text]
  • Antibody–Drug Conjugates
    Published OnlineFirst April 12, 2019; DOI: 10.1158/1078-0432.CCR-19-0272 Review Clinical Cancer Research Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index Steven Coats1, Marna Williams1, Benjamin Kebble1, Rakesh Dixit1, Leo Tseng1, Nai-Shun Yao1, David A. Tice1, and Jean-Charles Soria1,2 Abstract Since the first approval of gemtuzumab ozogamicin nism of activity of the cytotoxic warhead. However, the (Mylotarg; Pfizer; CD33 targeted), two additional antibody– enthusiasm to develop ADCs has not been dampened; drug conjugates (ADC), brentuximab vedotin (Adcetris; Seat- approximately 80 ADCs are in clinical development in tle Genetics, Inc.; CD30 targeted) and inotuzumab ozogami- nearly 600 clinical trials, and 2 to 3 novel ADCs are likely cin (Besponsa; Pfizer; CD22 targeted), have been approved for to be approved within the next few years. While the hematologic cancers and 1 ADC, trastuzumab emtansine promise of a more targeted chemotherapy with less tox- (Kadcyla; Genentech; HER2 targeted), has been approved to icity has not yet been realized with ADCs, improvements treat breast cancer. Despite a clear clinical benefit being dem- in technology combined with a wealth of clinical data are onstrated for all 4 approved ADCs, the toxicity profiles are helping to shape the future development of ADCs. In this comparable with those of standard-of-care chemotherapeu- review, we discuss the clinical and translational strategies tics, with dose-limiting toxicities associated with the mecha- associated with improving the therapeutic index for ADCs. Introduction in antibody, linker, and warhead technologies in significant depth (2, 3, 8, 9). Antibody–drug conjugates (ADC) were initially designed to leverage the exquisite specificity of antibodies to deliver targeted potent chemotherapeutic agents with the intention of improving Overview of ADCs in Clinical Development the therapeutic index (the ratio between the toxic dose and the Four ADCs have been approved over the last 20 years (Fig.
    [Show full text]
  • Federal Register Notice 5-1-2020 Pdf Icon[PDF – 358
    Federal Register / Vol. 85, No. 85 / Friday, May 1, 2020 / Notices 25439 confidential by the respondent (5 U.S.C. schedules. Other than examination DEPARTMENT OF HEALTH AND 552(b)(4)). reports, it provides the only financial HUMAN SERVICES Current actions: The Board has data available for these corporations. temporarily revised the instructions to The Federal Reserve is solely Centers for Disease Control and the FR Y–9C report to accurately reflect responsible for authorizing, supervising, Prevention the revised definition of ‘‘savings and assigning ratings to Edges. The [CDC–2020–0046; NIOSH–233–C] deposits’’ in accordance with the Federal Reserve uses the data collected amendments to Regulation D in the on the FR 2886b to identify present and Hazardous Drugs: Draft NIOSH List of interim final rule published on April 28, potential problems and monitor and Hazardous Drugs in Healthcare 2020 (85 FR 23445). Specifically, the develop a better understanding of Settings, 2020; Procedures; and Risk Board has temporarily revised the activities within the industry. Management Information instructions on the FR Y–9C, Schedule HC–E, items 1(b), 1(c), 2(c) and glossary Legal authorization and AGENCY: Centers for Disease Control and content to remove the transfer or confidentiality: Sections 25 and 25A of Prevention, HHS. withdrawal limit. As a result of the the Federal Reserve Act authorize the ACTION: Notice and request for comment. revision, if a depository institution Federal Reserve to collect the FR 2886b chooses to suspend enforcement of the (12 U.S.C. 602, 625). The obligation to SUMMARY: The National Institute for six transfer limit on a ‘‘savings deposit,’’ report this information is mandatory.
    [Show full text]
  • Polatuzumab Vedotin + Obinutuzumab + Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of a Phase Ib/II Trial
    Polatuzumab vedotin + obinutuzumab + lenalidomide in patients with relapsed/refractory follicular lymphoma: interim analysis of a phase Ib/II trial Catherine Diefenbach,1 Brad Kahl,2 Lalita Banerjee,3 Andrew McMillan,4 Rod Ramchandren,5,6 Fiona Miall,7 Javier Briones,8 Raul Cordoba,9 Eva Maria Gonzalez-Barca,10 Carlos Panizo,11 Jamie Hirata,12 Naomi Chang,13 Lisa Musick,12 Pau Abrisqueta14 1Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA; 2Division of Oncology, Washington University, St Louis, MO, USA; 3Oncology Centre, Maidstone and Tunbridge Wells NHS Trust, Kent, UK; 4Centre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK; 5Division of Oncology, University of Tennessee, Knoxville, TN, USA; 6Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA; 7Department of Haematology, University Hospitals of Leicester NHS Trust, Leicester, UK; 8Department of Hematology, Hospital Santa Creu i Sant Pau, Barcelona, Spain; 9Fundación Jiménez Díaz, Madrid, Spain; 10Institut Català D'Oncologia, Barcelona, Spain; 11Clínica Universidad de Navarra, Pamplona, Spain; 12Genentech, Inc., South San Francisco, CA, USA; 13F. Hoffmann-La Roche Ltd, Mississauga, Canada; 14Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain 1 Catherine Diefenbach http://bit.ly/2JjV5Jn Disclosures CD holds stock in Gilead Sciences; has a consulting/advisory role for Seattle Genetics, Bayer, Bristol-Myers Squibb, Genentech/Roche, and Merck; has received research funding from Seattle Genetics, Genentech, Incyte, LAM Therapeutics, Merck, Bristol-Myers Squibb, Millennium, and MEI Pharma. BK has a consulting/advisory role for Roche, Genentech, Celgene, AbbVie, Pharmacyclics, and Acerta Pharma; has received research funding from Genentech, Acerta Pharma, and BeiGene; has provided expert testimony for Genentech.
    [Show full text]
  • A Phase Ib/II Study Evaluating the Safety and Efficacy Of
    Official Title: A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Atezolizumab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination With Atezolizumab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma NCT Number: NCT02729896 Document Date: Protocol Version 8: 07-November-2018 PROTOCOL TITLE: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS POLATUZUMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS POLATUZUMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PROTOCOL NUMBER: BO29561 VERSION NUMBER: 8 EUDRACT NUMBER: 2015-004845-25 IND NUMBER: 128036 TEST PRODUCT: Obinutuzumab (RO5072759) Rituximab (RO0452294) Atezolizumab (RO5541267) Polatuzumab vedotin (RO5541077) MEDICAL MONITOR: , Ph.D. SPONSOR: F. Hoffmann-La Roche Ltd DATE FINAL: Version 1: 12 November 2015 DATES AMENDED: Version 2: 14 January 2016 Version 3: 28 June 2016 Version 4: 17 November 2016 Version 5: 4 May 2017 Version 6: 21 December 2017 Version 7: 1 May 2018 Version 8: See electronic date stamp below. PROTOCOL AMENDMENT APPROVAL Approver's Name Title Date and Time (UTC) Company Signatory 07-Nov-2018 02:00:10 CONFIDENTIAL This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F.
    [Show full text]
  • PD-1 / PD-L1 Combination Therapies
    PD-1 / PD-L1 Combination Therapies Jacob Plieth & Edwin Elmhirst – May 2017 Foreword Sprinkling the immuno-oncology dust When in November 2015 EP Vantage published its first immuno- oncology analysis we identified 215 studies of anti-PD-1/PD-L1 projects combined with other approaches, and called this an important industry theme. It is a measure of how central combos have become that today, barely 18 months on, that total has been blown out of the water. No fewer than 765 studies involving combinations of PD-1 or PD-L1 assets are now listed on the Clinicaltrials.gov registry. This dazzling array owes much to the transformational nature of the data seen with the first wave of anti-PD-1/PD-L1 MAbs. It also indicates how central combinations will be in extending immuno-oncology beyond just a handful of cancers, and beyond certain patient subgroups. But the combo effort is as much about extending the reach of currently available drugs like Keytruda, Opdivo and Tecentriq as it is about making novel approaches viable by combining them with PD-1/PD-L1. On a standalone basis several of the industry’s novel oncology projects have underwhelmed. As data are generated it will therefore be vital for investors to tease out the effect of combinations beyond that of monotherapy, and it is doubtful whether the sprinkling of magic immuno-oncology dust will come to the rescue of substandard products. This is not stopping many companies, as the hundreds of combination studies identified here show. This report aims to quantify how many trials are ongoing with which assets and in which cancer indications, as well as suggesting reasons why some of the most popular approaches are being pursued.
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]